Oncology

Latest News


A one-minute look at managed care news during the week of April 8, 2015, including a CMS announcing mental health parity and billions of dollars in unnecessary breast cancer care costs.

The scientists at Cancer Research UK, in collaboration with the University of Cambridge, have identified 77 changes in the DNA of individuals at an increased risk for breast cancer and have developed a "polygenic risk score" based on the changes.

Reaffirming previous trial results, the new study, published in International Journal of Radiation Oncology · Biology · Physics found that while radiation therapy had no impact on outcomes in head and neck cancer patients, it caused anemia in several.

In a related commentary in the same issue, Mark S. Talamonti, MD, of the NorthShore University HealthSystem, wrote, "With an aging population, this most formidable of human cancers will only increase in incidence and frequency. There is a clear and unequivocal need for affordable screening strategies based on reliable biomarkers and efficient imaging modalities."

Although the Affordable Care Act has helped more people gain access to healthcare coverage, including those with pre-existing conditions such as cancer, the survey by the Cancer Support Community found that the cost of care is still too high for many cancer patients.

In a large study conducted at the University of Pennsylvania in more than 31,000 women, scientists identified regions of both BRCA1 and BRCA2 that, when mutated, confer higher risks of ovarian cancer, and other regions that confer higher risk of breast cancer.

One day, cancer treatment regimens might include vaccines specially tailored to each patient. In a small preliminary study published in Science, researchers report successful use of these vaccines in 3 patients.

With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.

While supporting the FDA's standards-based regulatory efforts to explore next generation sequencing tests as diagnostic tools, the American Society of Clinical Oncology warned against misinterpretation or over-interpretation of test results.

Research published by a team of Italian scientists in the Journal of the National Institute of Cancer shows that a 13-gene panel blood test for microRNAs could be a cost-effective screening tool for lung cancer, compared with low-dose CT, which is expensive.

With an aim to grab band-width in the shared PD-1 space, Merck has partnered with Syntax to conduct combination studies of Keytruda with Entinostat in melanoma and lung cancer patients.